Enrollment completed in Phase 2a CBeyond trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead ...

The much-awaited launch of Mounjaro, an injectable drug used to treat obesity, overweight, and type 2 diabetes, has been ...

Mar. 3, 2025 — Obesity rates are set to skyrocket, with one in six children and adolescents worldwide forecast to be obese by 2050, according to a new study. But with significant increases ...

AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

North Yorkshire Council has been criticised by anti-obesity charities for making £90,000 from the sale of junk food and fizzy drinks at Harrogate district leisure centres. Council-owned leisure ...

He and his team then compared the diagnoses for hair loss in these patients’ medical records and found that those prescribed ...

Expensive processed meals and fatty, chemical-laden treats are highly profitable, as a trip to any supermarket, where they ...

Gemiglo is the first domestic diabetes medication brand to surpass 1 trillion won in sales. Sales of the Gemiglo product line ...

The administration is reviewing a Centers for Medicare and Medicaid Services rule that would expand coverage to Medicare and Medicaid recipients ...

Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

A league source confirmed to The Buffalo News on Wednesday morning that the Bills have a one-year contract agreement in place ...

With increasing demand and higher costs, ensuring appropriate patient access is more critical than ever and 2025 will likely ...